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Imputation of human leukocyte antigen (HLA) alleles from SNP-level data is attractive due
to importance of HLA alleles in human disease, widespread availability of genome-wide
association study (GWAS) data, and expertise required for HLA sequencing. However,
comprehensive evaluations of HLA imputations programs are limited. We compared HLA
imputation results of HIBAG, SNP2HLA, and HLA*IMP:02 to sequenced HLA alleles in
3,265 samples from BioVU, a de-identified electronic health record database coupled to a
DNA biorepository. We performed four-digit HLA sequencing for HLA-A, -B, -C, -DRB1,
-DPB1, and -DQB1 using long-read 454 FLX sequencing. All samples were genotyped
using both the Illumina HumanExome BeadChip platform and a GWAS platform. Call rates
and concordance rates were compared by platform, frequency of allele, and race/ethnicity.
Overall concordance rates were similar between programs in European Americans (EA)
(0.975 [SNP2HLA]; 0.939 [HLA*IMP:02]; 0.976 [HIBAG]). SNP2HLA provided a significant
advantage in terms of call rate and the number of alleles imputed. Concordance rates were
lower overall for African Americans (AAs). These observations were consistent when accu-
racy was compared across HLA loci. All imputation programs performed similarly for low fre-
quency HLA alleles. Higher concordance rates were observed when HLA alleles were
imputed from GWAS platforms versus the HumanExome BeadChip, suggesting that high
genomic coverage is preferred as input for HLA allelic imputation. These findings provide
guidance on the best use of HLA imputation methods and elucidate their limitations.
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Introduction
The major histocompatibility complex (MHC) and human leukocyte antigen (HLA) genes are
extensively studied due to their key role in immune response.[1] Human Leukocyte Antigen
(HLA) alleles have been implicated as risk factors for autoimmune diseases, infections, cancer,
and immune-mediated adverse drug reactions. The HLA region is characterized by high link-
age disequilibrium and a small number of single nucleotide polymorphisms (SNPs) can be
used to tag the majority of HLA alleles.[2] Consequently, HLA alleles are frequently imputed
from SNP-level data due to the widespread availability of genome-wide association study
(GWAS) data and the expense and expertise required to directly sequence HLA loci with four
digit resolution.[2] While HLA imputation programs have been applied successfully, notably
in disease immunopathology,[3,4,5] comparisons of the performance of commonly used pro-
grams are limited.[6] In addition, the performance of HLA imputation programs with respect
to the effect of genotyping platform, race/ethnicity, and frequency of HLA alleles is not well
studied.
Multiple approaches that impute HLA alleles from single nucleotide polymorphism (SNP)-
level data are available. Imputation methods include (1) HLA Genotype Imputation with Attri-
bute Bagging (HIBAG), which employs multiple expectation-maximization-based classifiers to
estimate the likelihood of HLA alleles;[7] (2) HLAIMP:02 which uses a haplotype graph-
based approach based on SNP data from multiple populations that can accommodate haploty-
pic diversity;[8] and (3) SNP2HLA which uses the imputation software package BEAGLE to
impute both HLA alleles and the amino acid substitutions for those classical alleles.[9] These
programs are freely available and have been used in published reports.[3,4,5]
Although the accuracy of these HLA imputation programs has been compared to sequence
data, few previous studies have directly compared their relative accuracies.[6,10] These studies
report varying results, were conducted in small homogeneous populations, looked only at class
II alleles, and do not test the effect of SNP genotyping platform, race/ethnicity, and HLA allele
frequency on imputation accuracy.[5,11,12] The present study compares imputation accuracy
of three widely-used programs in a large population with both European and African ances-




The study population was identified in BioVU, the Vanderbilt DNA databank that links DNA
extracted from discarded blood samples to de-identified electronic health records (EMRs).[13]
BioVU patients were enrolled from the Vanderbilt University Medical Center in Nashville,
TN. The study population was selected from the Vanderbilt Electronic Systems for Pharmaco-
genomic Assessment (VESPA) cohort, which aims to analyze DNA samples from the BioVU
database and EMRs to investigate the genetic underpinning for disease and drug response.
[14,15] This study was approved by the Institutional Review Board at Vanderbilt University as
described previously.[13,15]
HLA typing
Sequence based typing on a deep sequencing platform is currently considered the gold stan-
dard for class I and II high resolution. HLA typing High resolution, four-digit HLA sequenc-
ing was performed for HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DPB1, and HLA-DQB1 at
the Institute for Immunology and Infectious Diseases (IIID) at Murdoch University in Perth,
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Australia. The IIID is accredited by the American Society for Histocompatibility and Immuno-
genetics (ASHI) and the National Association of Testing Authorities (NATA) and the pipeline
described below has been used in multiple previous studies.[16,17] Specific HLA Loci were
PCR amplified using sample specific MID-tagged primers that amplify polymorphic exons
from class I (A, B, C exons 2 and 3) and class II (DQ, exons 2 and 3; DRB and DPB1, exon 1)
HLA loci. MID tagged primers have been optimized to minimize allele dropouts and primer
bias. Amplified DNA products from unique MID tagged products (up to 48 MIDs) were
pooled in equimolar ratios and subjected to library preparation, quantitation and emulsion
PCR suitable for entry into the 454 FLX sequencing pipeline for long read sequencing. Clonally
enriched beads were sequenced using 454 Titanium chemistry on a 454 FLX+ sequencer.
Sequences were separated by MID tags and alleles called using an in house accredited HLA
allele caller software pipeline that minimizes the influence of systematic sequencing errors in
454 data. Alleles were called using the latest IMGT HLA allele database as the allele reference
library. Sample to report integrity were tracked and checked using proprietary and accredited
Laboratory Information and Management System (LIMS) and HLA analysis reporting soft-
ware that performs comprehensive allele balance and contamination checks on the final data-
set. All samples that were successfully typed were included in the study population.
SNP-level genotyping
All samples included in this study population (n = 3,265) were genotyped using a genome-
wide platform, either the Illumina1 HumanOmni1-QUAD (n = 2,430 [74%]) or HumanOm-
ni5-QUAD BeadChip (n = 835 [26%]). The HumanOmni1-QUAD contains 11,675 SNPs in
the HLA region and the HumanOmni5-QUAD contains 26,952 SNPs in the HLA region
(GRCh37 chr6:28,477,797–33,448,354). In addition, 96% of the samples (n = 3,152) were also
typed using the Illumina1 HumanExome BeadChip, which contains putative functional
exonic variants and a small amount of non-exonic content including 2,061 HLA tagging SNPs.
SNP data from both the HumanExome BeadChip and GWAS platforms were cleaned using
the quality control (QC) pipeline developed by the eMERGE Genomics Working Group.
[18,19] Samples were classified as being of European or African descent (90% European
ancestry for European decent and80% African ancestry for African decent) using ancestry
informative markers (AIMs) from genome-wide platforms input into STRUCTURE using
Hapmap reference populations.[20] To further assess admixture, principal components analy-
sis (PCA) was also performed on GWAS data and compared to PCA generated using 1000
Genomes samples.
HLA allele imputation
Classical four digit HLA alleles were imputed from SNP data from HumanExome BeadChip
and GWAS platforms using HIBAG version 3,[7] HLAIMP:02,[8] and SNP2HLA (8/7/2102).
[9] The Type 1 Diabetes Genetics Consortium (T1DGC) reference panel was used for
SNP2HLA and HIBAG whereas HLAIMP:02 uses an internal reference panel. Individual dos-
ages for classical 4-digit alleles at HLA-A, -B, -C, -DQA1, -DQB1 and -DRB1 were imputed. A
posterior probability (PP) cutoff of 0.5 was implemented for imputed alleles based on previous
literature.[6,21] The three HLA imputation software programs were compared to sequenced
HLA alleles using the latest available version of each program. A sensitivity analysis was also
performed to account for imputed alleles with similar PPs. In our primary analysis, a given
sample could be assigned one imputed allele with a PP of 0.51 and another imputed allele with
a PP of 0.49, indicating minimal confidence of one imputed allele over the other. To exclude
HLA imputation comparison
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such imputations, the highest and second highest PP was used to calculate a posterior proba-
bility ratio and HLA allele calls were excluded if this ratio was less than 1.5.
Statistical analysis
The primary assessment metrics for each imputation program were concordance with
sequenced HLA type results and call rate. Call rate was defined as the number of imputed
alleles divided by the total number of individuals for which imputation was attempted. Con-
cordance was defined as the number of imputed four digit alleles matching sequenced alleles
divided by the total number of imputed alleles within the population. The calculation of con-
cordance thereby did not consider individuals for which alleles were not imputed. For
instance, if an imputation program did not impute an allele for an individual, this would not
affect the concordance rate, but the call rate would be decreased for that imputation program.
The total number of HLA alleles imputed by each program is also reported, which did not
require an individual within the population to possess that allele. We assessed the relative accu-
racy of the three imputation programs and the robustness of each program to differences in
race/ethnic group (European versus African ancestry), SNP genotyping platform (HumanEx-
ome BeadChip, HumanOmni1-QUAD, and HumanOmni5-QUAD), and frequency of HLA
allele (minor allele frequency less than 0.05 and 0.01).
Results
Our study population (n = 3,265) included 1,592 females (48.8%) and had an average age of
57.8 (standard deviation 20.8) years. Our population was comprised of 2,947 European Ameri-
cans (EAs) (90.2%) and 318 African Americans (AAs) by Structure-defined race. The average
percent European, African, and Asian ancestry for the European ancestry study population
was 98.2%, 1.0%, and 0.8% respectively and for the African ancestry study population, these
percentages were 17.7%, 79.1%, and 3.3%, respectively. Principal components analysis sug-
gested limited admixture in both the European and African ancestry study populations. (Fig 1)
SNP2HLA provided imputations for the largest overall number of HLA alleles at 210 com-
pared to HLAIMP:02 (140 alleles) and HIBAG (175 alleles). (Table 1) The performance was
excellent in EAs with overall concordance greater than 93% for all three programs. However,
performance was poorer in AAs with reduced concordance rates (0.919 [SNP2HLA]; 0.619
[HLAIMP:02]; 0.929 [HIBAG]). The overall concordance rate compared to HLA sequencing
was highest for HIBAG (97.6% in EAs and 92.9% in AAs) and SNP2HLA (97.5% in EAs and
91.9% in AAs) compared to HLAIMP:02 (93.9% in EAs and 61.9% in AAs). The overall call
rate was highest for SNP2HLA. (Table 1)
The concordance rate by HLA loci imputed from GWAS platforms (HumanOmni1-QUAD
and HumanOmni5-QUAD) ranged from 98.8% for SNP2HLA and HIBAG in HLA-DQB1 in
EAs and 41.4% for HLAIMP:02 in HLA-DRB1 in AAs. (Table 2) All programs had higher
concordance rates and call rates in EAs compared to AAs, although consistently higher call
rates were observed with SNP2HLA and consistently lower call and concordance rates were
observed with HLAIMP:02. Class I and class II HLA alleles were imputed with similar accu-
racy by all programs in EAs. In the sensitivity analysis implementing a posterior probability
ratio cutoff of 1.5, we observed slightly increased concordance rates and slightly decreased call
rates for each imputation program overall and by HLA locus. (S1 File)
When divided by platform, HLA imputation for each program had the highest concordance
when the HumanOmni5-QUAD platform, which included the largest number of genotyped
SNPs and the most comprehensive coverage in the HLA region, was used as input versus
HumanOmni1-QUAD. (Table 3) Concordance rates were lower when HumanExome
HLA imputation comparison
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Fig 1. Principal components analysis of 1000 Genomes samples and study population. Eigenvectors 1 and 2 are plotted to
determine racial decent and admixture of European and African Americans in the BioVU population. EA indicates European
American (BioVU); AA, African American (BioVU); CEPH, 1000 Genomes Utah Residents; ASW, Americans of African Ancestry
in Southwestern USA; MKK, Maasai in Kinyawa, Kenya; CHB, Han Chinese in Bejing, China; JPT, Japanese in Tokyo, Japan;
LWK, Luhya in Webuye, Kenya; YRI, Yoruba in Ibadan, Nigeria.
doi:10.1371/journal.pone.0172444.g001
Table 1. HLA imputation programs evaluation for all HLA alleles.
Race/Ethnicity Imputation Program Concordance Rate Call Rate Predicted Alleles (n)
European Americans (n = 2,947)1 SNP2HLA 0.975 1.00 210
HLA*IMP:02 0.939 0.985 140
HIBAG 0.976 0.978 175
African Americans (n = 318)2 SNP2HLA 0.919 0.999 174
HLA*IMP:02 0.619 0.768 134
HIBAG 0.929 0.584 131
Concordance and call rates generated from imputed alleles with posterior probability>0.50 versus sequenced alleles after combining data for
HumanOmni1-QUAD and HumanOmni5-QUAD platforms by race/ethnicity.
1) Based on sequencing, 325 distinct four digit alleles were present in the European American population.
2) Based on sequencing, 219 distinct four digit alleles were present in the African American population.
doi:10.1371/journal.pone.0172444.t001
HLA imputation comparison
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BeadChip data was used as input. SNP2HLA and HIBAG maintained high concordance rates
despite the loss of genomic coverage associated with the HumanExome BeadChip, whereas
HLAIMP:02 showed a greater decrease in concordance. These observations were consistent
in both EAs and AAs. All imputation programs performed well for low frequency alleles with
little differences in concordance rate for frequency<0.05 (0.981 [SNP2HLA]; 0.951
[HLAIMP:02]; 0.975 [HIBAG]) and for frequency<0.01 (0.979 [SNP2HLA]; 0.945
[HLAIMP:02]; 0.971 [HIBAG]). (Table 3)
Figs 2 and 3 show the frequency of imputed plotted against concordance rates by imputa-
tion program in EAs and AAs. These figures suggest that HLAIMP:02 underperformed in
terms of accuracy versus the SNP2HLA and HIBAG in both EAs and AAs. Although the
majority of low frequency alleles had high concordance rates, alleles with poor concordance to
Table 2. Concordance rate and call rate for each imputation program.
European Americans African Americans
Allele Imputation Program Concordance Rate Call Rate Concordance Rate Call Rate
HLA-A SNP2HLA 0.983 0.999 0.969 0.995
HLA*IMP:02 0.963 0.997 0.675 0.855
HIBAG 0.986 0.996 0.960 0.796
HLA-B SNP2HLA 0.969 1.00 0.884 1.00
HLA*IMP:02 0.952 0.979 0.423 0.752
HIBAG 0.978 0.967 0.953 0.403
HLA-C SNP2HLA 0.987 1.00 0.884 1.00
HLA*IMP:02 0.984 0.994 0.792 0.741
HIBAG 0.987 0.992 0.957 0.619
HLA-DPB1 SNP2HLA 0.957 1.00 0.945 1.00
HLA*IMP:02 0.829 0.987 0.567 0.708
HIBAG 0.957 0.975 0.834 0.475
HLA-DQB1 SNP2HLA 0.988 1.00 0.907 1.00
HLA*IMP:02 0.983 0.993 0.845 0.761
HIBAG 0.988 0.990 0.904 0.654
HLA-DRB1 SNP2HLA 0.964 1.00 0.920 1.00
HLA*IMP:02 0.924 0.961 0.414 0.791
HIBAG 0.959 0.946 0.946 0.557
Concordance and call rates generated from imputed alleles with posterior probability>0.50 versus sequenced alleles after combining data for
HumanOmni1-QUAD and HumanOmni5-QUAD platforms by HLA locus and race/ethnicity.
doi:10.1371/journal.pone.0172444.t002
Table 3. Concordance rates and call rates for imputation programs for all HLA loci by platform and allele frequency in European Americans.
SNP2HLA HLA*IMP:02 HIBAG
Platform HumanExome BeadChip .969/.999 .892/.950 .976/.973
HumanOmni1-QUAD .975/1.00 .939/.985 .976/.978
HumanOmni5-QUAD .975/1.00 .938/.985 .975/.977
HumanOmni1-QUAD / HumanOmni5-QUAD .976/1.00 .942/.986 .979/.979
HLA allele Frequency1 Freq.<0.05 .981/- .951/- .975/-
Freq.<0.01 .979/- .945/- .971/-
Freq. indicates frequency cutoff; HLA, human leukocyte antigen.
1) Call rates not estimated when frequency cutoffs were implemented
doi:10.1371/journal.pone.0172444.t003
HLA imputation comparison
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sequence data were likely to be low frequency alleles. Concordance rates for individual alleles
are listed in the Supplemental Materials (S1 File). Table 4 compares concordance and call rates
of common HLA alleles previously associated with autoimmune disease and adverse drug
reactions. These disease-associated alleles had high concordance rates for all imputation pro-
grams in EAs, but a large decrease in accuracy was observed for disease-associated allele in
AAs.
Discussion
We provide a detailed evaluation and comparison of three commonly used HLA imputation
programs. Overall, the programs performed similarly in terms of concordance with sequence
data in EAs. We observed that HLA imputation accuracy was decreased in AAs and when
using genotyping platforms with lower HLA coverage as input. However, SNP2HLA was
observed to predict a greater number of HLA alleles with a higher call rate and was most robust
when using a platform with limited genomic coverage and when imputing alleles in AAs.
Overall, we observed similar concordance rates to sequence results when compared with
previous studies.[6,10,21] Our data are also consistent with previous studies which have shown
that imputation accuracy was decreased in non-Caucasian populations.[6,22] The decrease in
accuracy in AAs may have been due to a reduced linkage disequilibrium structure in this race
group. Reduced imputation accuracy in AAs may also have been due to the use of the T1DGC
as a reference panel, since the T1DGC consists primarily of patients of European descent and
previous studies have shown that HLA imputation accuracy is highly dependent on the racial
similarity between the test and reference populations.[6,10,21] If individuals in our population
Fig 2. Allele frequency versus concordance rates of HLA alleles by imputation program in European
Americans. Concordance rates were generated using OMNI1 and OMNI5 combined SNP-level data and
posterior probability >0.50 for each imputation program.
doi:10.1371/journal.pone.0172444.g002
HLA imputation comparison
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carry an HLA allele that is rare or absent from the individuals in the reference panel, the allele
would not be imputed. Comparisons of HLA imputation programs in admixed populations
are limited. For SNP2HLA, overall imputation accuracies for AAs in this study were high rela-
tive to other studies, possibly indicating high European admixture in the AA BioVU popula-
tion. This observation suggests that SNP2HLA is preferred when an admixed population
without a representative reference population is available.
We observed a higher HLA imputation accuracy for each program studied when input
genotype data had greater coverage in the HLA region. Our data suggest a preference for
genome-wide platforms with greater genomic coverage when imputing HLA alleles. However,
HLA imputation was still high when data from the HumanExome BeadChip, which has 2,061
HLA tags, was used as input, suggesting that valuable information can still be gained in the
absence of high coverage genome-wide platforms. Our results are consistent with a previous
report for HLA-DRB1 alleles in a Finnish population (n = 161) using HLAIMP and
SNP2HLA, which reported that SNP coverage and quality did not markedly affect HLA impu-
tation results.[10] We found a slight but consistent increase in the accuracy of HLA imputation
for all programs when genomic coverage of the input platform was increased. We also
observed that SNP2HLA was the most robust program with respect to maintaining accuracy
despite a loss of genomic coverage.
Although each of the three HLA imputation programs evaluated performed similarly,
SNPHLA was observed to have the best accuracy call rates overall for most of the analyses per-
formed. SNP2HLA provided a significant advantage in the number of alleles imputed and out-
performed the other two programs in our AA population. The high number of alleles imputed
Fig 3. Allele frequency versus concordance rates of HLA alleles by imputation program in African
Americans. Concordance rates were generated using OMNI1 and OMNI5 combined SNP-level data and
posterior probability>0.50 for each imputation program.
doi:10.1371/journal.pone.0172444.g003
HLA imputation comparison
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with high accuracy offers advantages especially when uncommon alleles are included in analy-
ses. SNP2HLA was also observed to maintain imputation accuracy when genomic coverage
was decreased and when imputing alleles for AA individuals. These data suggest that
SNP2HLA should be used in preference to HLAIMP:02 and HIBAG in similar populations
genotyped on similar platforms.
Since all programs tested had high concordance rates for most alleles in EAs, with the
HumanExome BeadChip as input, and in low frequency alleles, selection of HLA programs
based on other factors would be reasonable when HLA alleles are being imputed for a homoge-
neous EA population. Such factors might include data output, computing time, and availability
and flexibility of appropriate reference panels. Although all programs impute all the alleles
tested in this study, other alleles such as those in HLA-DPA1 are not imputed in all programs.
SNP2HLA also offers output which includes two digit HLA alleles, HLA amino acid changing
polymorphisms, and phased output files. However, SNP2HLA has a computational restriction
which may force sub-setting of data. In any case, imputation from SNP data may be useable in
research setting with large numbers of samples but not likely to have accuracy to justify use in
clinical practice.[23]
The strengths of our study include a large sample size relative to previous publications as
well as the inclusion of multiple platforms with varying HLA region coverage. Unlike previous
studies, we have performed an extensive set of comparisons within a single population, includ-
ing both class I and II HLA alleles and multiple race groups, including an admixed US
Table 4. Concordance rate and call rate for important disease-associated and adverse drug reaction-associated alleles.
HLA Allele Disease/ADR Imputation Program Concordance Rate (EAs)1 Concordance Rate (AAs)1
B*27:05 ankylosing spondylitis[24] SNP2HLA 0.948 0.667
HLA*IMP:02 0.936 0.250
HIBAG 0.933 1.000
B*57:01 abacavir HSN[17]; flucloxacillin DILI[25] SNP2HLA 0.996 1.000
HLA*IMP:02 0.978 0.118
HIBAG 0.975 1.000
B*58:01 allopurinol SJS/TEN[26] SNP2HLA 1.000 0.857
HLA*IMP:02 1.000 0.621
HIBAG 0.964 0.783
DQB1*02:01 Sjogren’s Syndrome[27] SNP2HLA 0.980 0.518
HLA*IMP:02 0.997 0.957
HIBAG 0.997 0.698
DRB1*03:02 Lupus erythematosus[28] SNP2HLA 0.750 1.000
HLA*IMP:02 - -
HIBAG 1.000 0.951
DRB1*08:01 primary biliary cirrhosis[29] SNP2HLA 0.978 1.000
HLA*IMP:02 0.882 0.154
HIBAG 0.951 -
DRB1*04:01 rheumatoid arthritis[30] SNP2HLA 0.951 0.889
HLA*IMP:02 0.856 0.179
HIBAG 0.927 0.158
Concordance rates were generated using HumanOmni1-QUAD and HumanOmni5-QUAD combined SNP-level data and posterior probability>0.50 for each
imputation program by HLA locus and race/ethnicity. HLA indicates human leukocyte antigen; EA, European American; AA, African American; HSN,
hypersensitivity; DILI, drug-induced liver injury; NA, not applicable; SJS, Stevens-Johnson Syndrome; TEN, toxic epidermal necrosis
1) “-”indicates that the imputation program did not impute the allele.
doi:10.1371/journal.pone.0172444.t004
HLA imputation comparison
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population. Our study has several limitations worthy of mention. A reference population spe-
cific to our AA population was not used and this likely contributed to reduced imputation
accuracy. However, SNP2HLA was robust in terms of concordance rates in AAs, suggesting
that the T1DGC reference population may be sufficient in an admixed US population of AAs.
Our approach underscores the limited availability of appropriate reference panels of HLA
alleles for non-Caucasian individuals. We also did not sequence HLA-DQA1 and–DPA1 alleles
and, thus, no comparison was possible for these alleles, although the variability within these
genes is known to be low. We also did not examine differences in strand concordance for HLA
alleles among the HLA imputation programs. Sequence based typing on a deep sequencing
platform is currently considered the gold standard for class I and II high resolution HLA typ-
ing, but it can be limited by the smaller number of laboratories that have this expertise and the
expense and turnaround time of typing. Since only successfully sequenced samples were
included, samples that might have been difficult to sequence were not reflected in our analysis.
Although we did compare imputation accuracy using the HumanOmni5-QUAD and Huma-
nOmni1-QUAD platforms as input, we did not genotype samples on both platforms and so
these platforms were compared in different subsets of patients. Finally, the racial makeup of
the BioVU population precluded an evaluation and comparison of HLA imputation methods
in other race/ethnic groups such as Asians or Hispanics.
In most scenarios tested, SNP imputation programs performed similarly in terms of con-
cordance. However, SNP2HLA typically had the highest concordance with robust call rates
and provided a significant advantage in the number of alleles imputed. All programs resulted
in better concordance in EAs versus AAs and performed similarly for low frequency alleles.
Our results suggest that high genomic coverage is preferred as input for HLA allelic imputa-
tion. These observations are useful to provide guidance on the best use of HLA imputation
methods and elucidate their limitations.
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